Eleven Biotherapeutics (EBIO) Misses Q3 EPS by 17c

Eleven Biotherapeutics (NASDAQ: EBIO) reported Q3 EPS of ($0.50), $0.17 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $68 thousand versus the consensus estimate of $100 thousand.

For earnings history and earnings-related data on Eleven Biotherapeutics (EBIO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c